HX-009

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameHX-009
Drug Alias NameHX-009HX009-II-02
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 blockersSignal-regulatory protein alpha inhibitors
TargetsProgrammed cell death protein 1Signal-regulatory protein alpha
Therapy Area/IndicationsSolid tumoursLiver NeoplasmsStomach Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesWaterstone Hanxbio Pty Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWaterstone Hanxbio Pty LtdWuhan Hanxiong Biotechnology Co LtdHanx Biopharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursBile Duct NeoplasmsBiliary Tract Neoplasms +[6] 
Inactive IndicationsLiver NeoplasmsStomach Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A